Not too early to consider funding for, distribution of malaria vaccine

In this Huffington Post opinion piece, Orin Levine, executive director of the International Vaccine Access Center of Johns Hopkins University, notes some of the parallels between the development of RTS,S, the experimental malaria vaccine currently being tested in Africa, and the polio vaccine, but he says "there are also some particularly disappointing ways in which the polio and malaria efforts could differ."

Shortly after the success of the polio vaccine was announced in 1955, it "was licensed, ... multiple manufacturers immediately lined up to produce the vaccine," and "the U.S. government stepped up to pay for the vaccine," Levine writes. The malaria vaccine's "latest achievement should serve as an early signal for all parties to begin working earnestly to anticipate and overcome vaccine access issues," he says, adding that "donors need to decide how their support will be used to fund this vaccine," such as through the GAVI Alliance, and "the manufacturer and the buyers (whomever is chosen) need to begin discussions about pricing and volumes of vaccine now -- and need to move toward making development and purchasing commitments" (10/27).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New vaccine shows potential in preventing recurrence of triple-negative breast cancer